Cytokinetics ACACIA-HCM Phase 3 Hits Both Primary Endpoints; sNDA Planned for Q4
CYTK has more than doubled off its 52-week low of $35.22.
Summary
Cytokinetics announced positive full results from the ACACIA-HCM Phase 3 trial of aficamten in non-obstructive HCM, meeting both primary endpoints and planning an FDA submission in Q4 2026.
Key Events · Product Development and Regulatory · CYTK
-
ACACIA-HCM Meets Both Primary Endpoints
Aficamten showed statistically significant improvements vs placebo in KCCQ-CSS (LSM difference 3.0, p=0.021) and pVO2 (0.67 mL/kg/min, p=0.003) at Week 36 in non-obstructive HCM.
-
First Positive Phase 3 in nHCM
ACACIA-HCM is the first Phase 3 trial to demonstrate statistically significant improvements across both patient-reported and physician-assessed endpoints in non-obstructive HCM, a population with no approved disease-modifying therapy.
-
sNDA Submission Planned for Q4 2026
Cytokinetics will submit a supplemental New Drug Application to the FDA for aficamten in symptomatic nHCM in the fourth quarter of 2026.
-
Safety Profile Shows LVEF Reductions
LVEF <50% occurred in 10.5% of aficamten patients vs 0.8% on placebo; serious adverse events were 20.2% vs 14.7%. Most LVEF events were manageable with dose adjustment.
Analysis · CYTK · Life Sciences
The full ACACIA-HCM results confirm aficamten's efficacy in non-obstructive HCM, a patient population with no approved disease-modifying therapy. Both dual primary endpoints were met with statistical significance, and the company will submit a supplemental New Drug Application to the FDA in Q4 2026. This expands the addressable market for aficamten beyond the already-approved obstructive HCM indication, potentially doubling the treatable patient population. Safety signals — notably LVEF <50% in 10.5% of treated patients versus 0.8% on placebo — warrant monitoring but did not derail the positive efficacy readout.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYTK was trading at $73.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8B. The 52-week trading range was $35.22 to $88.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.